赛伦生物(688163) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 reached RMB 196.21 million, a year-on-year increase of 0.66%[5] - Operating profit was RMB 62.04 million, reflecting a growth of 19.34% compared to the previous year[5] - Net profit attributable to shareholders of the parent company was RMB 51.71 million, up 16.76% year-on-year[5] - Net profit excluding non-recurring gains and losses increased by 50.65% to RMB 42.56 million[8] - Basic earnings per share rose to RMB 0.48, an increase of 17.07%[3] Assets and Equity - Total assets at the end of the reporting period were RMB 1,162.94 million, a 3.83% increase from the beginning of the period[6] - Equity attributable to shareholders of the parent company was RMB 1,112.58 million, up 1.56%[6] Profitability and Growth Factors - The company’s gross profit margin remained stable despite a slight increase in revenue[7] - The launch of the anti-rabies serum in the second half of 2025 is expected to contribute to future revenue growth[7] - The company has noted a decrease in non-recurring gains and losses, primarily due to reduced investment income from structured deposits and government subsidies[8]